MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ALGS had $11,741K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$11,741K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Accounts payable
    • Stock-based compensation includi...
    • Others
Negative Cash Flow Breakdown
    • Change in fair value of 2023 com...
    • Accrued liabilities
    • Operating lease liabilities
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net (loss) income, as reported
-23,040 -19,881 -31,537 27,225
Accretion of discount on investments
419 444 710 1,034
Non cash lease expense
509 492 478 905
Change in fair value of 2023 common warrants
-3,395 -1,213 4,205 -63,176
Depreciation expense
346 257 220 453
Stock-based compensation including espp
1,314 1,458 1,467 2,119
Deferred revenue
--168 -411 428
Accounts payable
3,657 -669 752 1,328
Accrued liabilities
-1,537 -79 1,400 -3,352
Operating lease liabilities
-834 -817 -796 -1,499
Other liabilities
-47 ---
Other assets
-318 681 -587 -190
Net cash and cash equivalents used in operating activities
-23,128 -21,745 -24,345 -36,413
Maturities of short-term investments
35,000 37,500 70,000 20,000
Purchase of short-term investments
-39,429 22,124 103,336
Purchases of property and equipment
-69 -92 -193 -152
Net cash and cash equivalents provided by (used in) investing activities
34,931 -2,021 47,683 -83,488
Proceeds from the espp purchase
-124 0 180
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs
-2 -43 101,386
Payments on finance lease
62 3 10 1
Net cash and cash equivalents (used in) provided by financing activities
-62 123 -53 101,565
Net increase in cash, cash equivalents, and restricted cash
11,741 -23,643 23,285 -18,336
Cash, cash equivalents, and restricted cash, beginning of period
18,413 42,056 37,107 -
Cash, cash equivalents, and restricted cash, end of period
30,154 18,413 42,056 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of short-terminvestments$35,000K Net cash and cashequivalents provided by...$34,931K Canceled cashflow$69K Net increase incash, cash...$11,741K Canceled cashflow$23,190K Purchases of property andequipment-$69K Accounts payable$3,657K Stock-based compensationincluding espp$1,314K Non cash leaseexpense$509K Depreciation expense$346K Other assets-$318K Net cash and cashequivalents used in...-$23,128K Net cash and cashequivalents (used in)...-$62K Canceled cashflow$6,144K Net (loss) income,as reported-$23,040K Change in fair value of2023 common warrants-$3,395K Payments on finance lease$62K Accrued liabilities-$1,537K Operating leaseliabilities-$834K Accretion of discount oninvestments$419K Other liabilities-$47K

Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc. (ALGS)